 | • レポートコード：MRC2106A060 • 出版社/出版日：Mordor Intelligence / 2021年5月20日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、尿路上皮がん治療薬の世界市場について調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（化学療法、免疫療法）分析、地域別分析、競争状況、市場機会・未来動向などを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・尿路上皮がん治療薬の世界市場規模：治療別（化学療法、免疫療法） ・尿路上皮がん治療薬の世界市場規模：地域別 ・競争状況 ・市場機会・未来動向 |
The urothelial cancer drugs market studied was projected to grow with a CAGR of 15.5% over the forecast period.
The emergence of COVID-19 has had a profound impact on the Urothelial Cancer Drugs market as well. As per the data provided by National Health Services, England on ‘NHS Diagnostic Waiting Times and Activity Data’, 2020, stated that the healthcare services had been devastated globally. As of August 2020, approximately 50.2% of the patients, in England, for cystoscopy had to wait for at least 6 weeks as compared to 9% in the year,2019. Thus, this delay in diagnosis impacted negatively on the therapeutic interventions as well and thereby limiting the market studied.
Some of the major factors that are bolstering the market growth are the emergence and popularity of targeted therapy and the rise in the incidence of urothelial cancer. Bladder cancer is the 10th most common malignancy across the world, according to the GLOBOCAN 2020, and the most frequently occurred type of bladder cancer is urothelial carcinoma.
As per the study titled, ‘Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths’, published in December 2019, about 79.3% of the bladder cancer patients were of transitional cell carcinoma. an additional 6% showed associated squamous features.
In addition, the urothelial cancer drugs market is likely to be benefitted from better therapies being approved by prominent drug regulatory organizations. In April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene for the treatment of advanced/metastatic urothelial carcinoma. Several novel treatments are predicted to see approvals, further supporting the growth of the market.
Key Market Trends
Chemotherapy Under the Treatment Type is Expected to Witness the Fastest Growth Over the Forecast Period
The chemotherapy segment is expected to dominate the market by treatment type, as the drugs may be used alone or in combination, depending on the purpose of their usage. The delay in diagnosis and treatment during the pandemic situation is expected to have adversely affected the demand for chemotherapy drugs as well in the year 2020.
However, according to the Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, treatment regimens for cancer management had been modified to minimize the number of visits. They also found that patients receiving chemotherapy treatment were not at high risk of developing COVID-19. Such studies are expected to positively impact the market studied in this segment.
Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of urothelial cancer cells. It works throughout the whole body to destroy and damage cancer cells that have spread to other parts of the body away from the original tumor.
The chemotherapy product launches and approvals for urothelial cancer are expected to boost the market growth. For instance, In December 2019, the United States Food and Drug Administration approved Padcev (enfortumab vedotin-ejfv) developed by Astellas Pharma US, Inc. and Seattle Genetics, Inc. It has been indicated against the treatment of advanced urothelial cancer.
Furthermore, as per the results of ‘Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial’, published in March 2020, gemcitabine-platinum combination chemotherapy significantly improved the outcomes in patients suffering from upper tract urothelial carcinoma. Such studies are expected to aid the market growth in this segment.
North America Dominates the Market and Expected to Follow the Same Trend Over the Forecast Period
The North American region has been dominating the urothelial cancer drugs market. With the emergence of COVID-19, a significant impact on the urothelial cancer drugs market was also observed. As result organizations such as the American College of Surgeons (ACS)have released recommendations in order to guide appropriately on the treatment delays.
Due to factors, such as the presence of a large target population, increased adoption of novel therapeutics, and multiple product launches, along with a rising need to tackle bladder cancer. As per the data of GLOBOCAN, in 2020, about 90,000 new cases of bladder cancer were reported in North America, and in 2040 this number is expected to reach 137,000 in North America. Most of the bladder cancer cases are urothelial cancer types. Thus, the rising burden of bladder cancer, the burden of urothelial cancer is also expected to increase. With a large number of bladder cancer cases, increased awareness in the society, and healthcare facilities with good distribution channels are some of the important factors, which makes the market in the region grow well over the forecast period.
Competitive Landscape
The urothelial cancer drug market is consolidated and however, it is expected to grow at a rapid pace in the next couple of years with intense competition among the players and a rising number of cases. Few key players are already being observed adapting strategies such as collaboration for the development of therapies and drugs, which would likely make the urothelial cancer drugs market crowded with new products in the next couple of years. Some of the major players in the urothelial cancer drugs market are Merck & Co. Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, and Novartis AG, among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Emergence and Priority of Targeted Therapy Among Biopharmaceutical Companies
4.2.2 Growing Burden of Urothelial Cancer
4.3 Market Restraints
4.3.1 Side Effects Associated with Drugs
4.3.2 Regulatory Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Chemotherapy
5.1.2 Immunotherapy
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 F. Hoffmann-La Roche AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 AstraZeneca PLC
6.1.5 Novartis AG
6.1.6 GlaxoSmithKline PLC
6.1.7 Sanofi SA
6.1.8 Eisai Co. Ltd
6.1.9 Astellas Pharma
6.1.10 UroGen Pharma
6.1.11 Pfizer Inc.
6.1.12 Genentech USA Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS